OnDemand
State of the Heart 2022
  • Detail & Program Access
  • Overview & Objectives
  • Credit Eligibility
  • Agenda
  • Program Materials
  • Funding Support
View Session 1

View Session 2

View Session 3

Program Access and Details:

Program Length:
90 minutes x 3

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
The OnDemand version of this program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

Virtual Exhibit Hall:
Please click the link below to access the program virtual exhibit hall.

Virtual Sponsor Exhibit
program advertising tile
View Session 1

View Session 2

View Session 3

Program Access and Details:

Program Length:
90 minutes x 3

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
The OnDemand version of this program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

program advertising tile

SESSION 1 - LEARNING OBJECTIVES

  • Explore current role of GLP-1 agonists in clinical practice
  • Recognize the impact of kidney protection for cardiac protection
  • Determine when to use medical vs surgical treatment in stable CAD
  • Describe appropriate antiplatelet therapy for stable CAD patients

SESSION 2 - LEARNING OBJECTIVES

  • Describe a guidelines centric approach to manage and support patients with obesity
  • Distinguish the appropriate use of ezetimibe or PCSK9 inhibitors in secondary prevention
  • Discuss the role of a new market entrance in lipid management
  • Apply guideline centric strategies for managing cardiovascular risk beyond LDL-C

SESSION 3 - LEARNING OBJECTIVES

  • Summarize the benefits and challenges with using DOAC’s
  • Describe appropriate management strategies and therapies for managing patients with HFrEF and HFpEF
  • Explore developments in cardiovascular medicine that may change how we treat patients in the future

The OnDemand recordings of this live program are NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

Program Chapter
Presenter
SEESION ONE
GLP-1 agonists: underused and underappreciated?
Darren McGuire
CKD: save the kidneys, save the heart
David Cherney
Stable CAD: when to use antianginals and when to revascularize
Tara Sedlak
Stable CAD: ASA alone, prolonged DAPT or low-dose rivaroxaban?
Marc S. Sabatine
SESSION TWO
Have we entered a new era in obesity management?
Megha Poddar
When to use ezetimibe or PCSK9 inhibitors in secondary prevention
Jacques Genest
Inclisiran: the new LDL kid on the block
Milan Gupta
Cardiovascular risk reduction: more than just LDL-C
Deepak Bhatt
SESSION THREE
Lessons learned after a decade of experience with DOAC’s
Paul Dorian
HFrEF: how to start and titrate the four pillars of treatment
Nadia Giannetti
HFpEF: which drugs have become standard of care?
Milan Gupta
CV medicine in the next decade: predicting the future
Deepak Bhatt

Program slides:

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.

Access CCRN Member Resource Library.

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and was supported through an educational grant received from Gold: HLS Therapeutics; Silver: AstraZeneca, Bayer, BMS/Pfizer Alliance, Boehringer Ingelheim, Janssen, KYE Pharmaceuticals, Sanofi and in-kind support from Pfizer.

 

 

 

 

 

 

 

 

 

 

© 2020-2021 MDLearn, All Rights are Reserved